kangaSue
Senior Member
- Messages
- 1,896
- Location
- Brisbane, Australia
In light of my personal experience, I think there is a case for further evaluation of Nicorandil as a potential treatment in ME/CFS.
To give a brief overview of my situation, I do not have CFS, my issue is chronic idiopathic Gastroparesis (GP). I have been enteral tube feeding for 10 years, had increasing gut pain over the last 5 years, had low resting blood pressure and bradycardia but no other cardiac defect. Recently found to have bowel ischemia from lack of blood flow to the bowel, diagnosed as Non-occlusive Mesenteric Ischemia (NOMI) as no physical obstruction or artery defect was evident in the Mesentery arteries.
I have not been able to tolerate analgesics in any form due to the GP and was desperate enough to trial Nicorandil on the strength of a brief mention in the only citation I could find that referred to its pain reliever effect outside of a cardiac setting: http://www.ncbi.nlm.nih.gov/pmc/articles/pmc2778114 (refer to NOMI under heading Chronic Splanchnic Syndrome)
My U.K. Trained motility specialist has since endorsed my use of Nicorandil and was aware of it being used in Europe in cases of bowel ischemia (but didn't mention it when I sought her help 3 months earlier. I discovered it myself when trying to prove to this specialist my self-diagnosis of Mesenteric Ischemia as CT Angiogram showed no blockage or impediment of blood flow).
The result of taking Nicorandil has been somewhat remarkable;
In the absence of any documented human trials or clinical studies that I can find (I am not particularly accomplished with technology and have no medical or scientific training), my improvement might just be an isolated case but if a drug to treat ischemia in cardiac smooth muscle cells also relieves ischemia in gastric smooth muscle cells then I think its fair to assume that ischemia in other smooth muscle cells in other parts of the body has a good chance of responding similarly.
If I also make the assumption that CFS symptoms in some cases is due, in part, to low blood pressure resulting in poor blood flow to smooth muscle cells resulting in ischemic pain and or reperfusion injury, then it may be concluded that Nicorandil could have a role in treating CFS.
My (limited) understanding of the technical aspect of Nicorandil is that it is a Pyridal nitrate, classed as a potassium channel opener, whose intrinsic mechanism is the selective activation of K+ ATP channels at the sarcolemmal and mitochondrial level, effecting the relaxation of smooth muscle cells and vasodilation of both coronary and peripheral arteries.
It has been demonstrated to have cardio-protective action against ischemia/reperfusion injury, protecting mitochondria from further injury. Not sure if I saw that in relation to human trials or just animal models but as I understand it, it is generally accepted that ischemia/reperfusion injury disrupts mitochondrial energy metabolism, a common belief I often see expressed among those in the CFS community.
All I really know for certain is that as a human guinea pig, Nicorandil works for me in treating bowel ischemia
As per normal, this drug is not available in many countries but it is reported that the majority of potassium channel opener drugs have a similar vasorelaxant action. There are a lot of new PCO's in the development pipeline such as Iptakalim, Aprakalim and Rimakilim but the likes of Flupirtine, a non-opiate, non-nsaid, non-steroidal analgesic drug has been in use in Europe for over 30 years and its biosostere, Ezogabine (also called Retigabine in some markets) has recently entered the American market, albeit as an anti-seizure drug with a reduced analgesic effect. These are not recommendations, only other options to further evalue.
http://ncbi.nlm.nih.gov/pubmed/18221232
http://ncbi.nlm.nih.gov/pubmed/15464034
http://ncbi.nlm.nih.gov/pubmed/11919514
http://ncbi.nlm.nih.gov/pubmed/20839897
To give a brief overview of my situation, I do not have CFS, my issue is chronic idiopathic Gastroparesis (GP). I have been enteral tube feeding for 10 years, had increasing gut pain over the last 5 years, had low resting blood pressure and bradycardia but no other cardiac defect. Recently found to have bowel ischemia from lack of blood flow to the bowel, diagnosed as Non-occlusive Mesenteric Ischemia (NOMI) as no physical obstruction or artery defect was evident in the Mesentery arteries.
I have not been able to tolerate analgesics in any form due to the GP and was desperate enough to trial Nicorandil on the strength of a brief mention in the only citation I could find that referred to its pain reliever effect outside of a cardiac setting: http://www.ncbi.nlm.nih.gov/pmc/articles/pmc2778114 (refer to NOMI under heading Chronic Splanchnic Syndrome)
My U.K. Trained motility specialist has since endorsed my use of Nicorandil and was aware of it being used in Europe in cases of bowel ischemia (but didn't mention it when I sought her help 3 months earlier. I discovered it myself when trying to prove to this specialist my self-diagnosis of Mesenteric Ischemia as CT Angiogram showed no blockage or impediment of blood flow).
The result of taking Nicorandil has been somewhat remarkable;
- I had a better than 90% reduction in pain overnight.
- Within a week my resting blood pressure was up.
- Within 2 weeks I was tolerating oral nutrition supplements.
- Within 4 weeks I ceased tube feeding altogether as I could eat 3 small meals a day with a calorie top up from the liquid supplements.
- This was the first newly introduced medication, vitamin or supplement that I have been able to tolerate for over 7 years.
- I had a better than 90% reduction in pain overnight.
In the absence of any documented human trials or clinical studies that I can find (I am not particularly accomplished with technology and have no medical or scientific training), my improvement might just be an isolated case but if a drug to treat ischemia in cardiac smooth muscle cells also relieves ischemia in gastric smooth muscle cells then I think its fair to assume that ischemia in other smooth muscle cells in other parts of the body has a good chance of responding similarly.
If I also make the assumption that CFS symptoms in some cases is due, in part, to low blood pressure resulting in poor blood flow to smooth muscle cells resulting in ischemic pain and or reperfusion injury, then it may be concluded that Nicorandil could have a role in treating CFS.
My (limited) understanding of the technical aspect of Nicorandil is that it is a Pyridal nitrate, classed as a potassium channel opener, whose intrinsic mechanism is the selective activation of K+ ATP channels at the sarcolemmal and mitochondrial level, effecting the relaxation of smooth muscle cells and vasodilation of both coronary and peripheral arteries.
It has been demonstrated to have cardio-protective action against ischemia/reperfusion injury, protecting mitochondria from further injury. Not sure if I saw that in relation to human trials or just animal models but as I understand it, it is generally accepted that ischemia/reperfusion injury disrupts mitochondrial energy metabolism, a common belief I often see expressed among those in the CFS community.
All I really know for certain is that as a human guinea pig, Nicorandil works for me in treating bowel ischemia
As per normal, this drug is not available in many countries but it is reported that the majority of potassium channel opener drugs have a similar vasorelaxant action. There are a lot of new PCO's in the development pipeline such as Iptakalim, Aprakalim and Rimakilim but the likes of Flupirtine, a non-opiate, non-nsaid, non-steroidal analgesic drug has been in use in Europe for over 30 years and its biosostere, Ezogabine (also called Retigabine in some markets) has recently entered the American market, albeit as an anti-seizure drug with a reduced analgesic effect. These are not recommendations, only other options to further evalue.
http://ncbi.nlm.nih.gov/pubmed/18221232
http://ncbi.nlm.nih.gov/pubmed/15464034
http://ncbi.nlm.nih.gov/pubmed/11919514
http://ncbi.nlm.nih.gov/pubmed/20839897